SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Acrivon Therapeutics (ACRV) Reports $77.8M Cash, Runway Into Q4 2027

Acrivon reported a Q3 2026 net loss of $17.9M versus $18.2M in Q3 2025. It had $77.8M in cash, cash equivalents and investments at September 30, 2026, expected to fund operations into Q4 2027.Material DetailsContext by AI AnalystThis update combines quarterly financial results with pipeline expansi…

ACRV

Related stories